Ignite Creation Date:
2024-05-06 @ 8:07 AM
Last Modification Date:
2024-10-26 @ 11:57 AM
Study NCT ID:
NCT02679755
Status:
COMPLETED
Last Update Posted:
2022-07-27
First Post:
2016-01-22
Brief Title:
Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR HER2- Advanced Breast Cancer
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A STUDY OF PALBOCICLIB IN COMBINATION WITH LETROZOLE AS TREATMENT OF POST-MENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER FOR WHOM LETROZOLE THERAPY IS DEEMED APPROPRIATE
Status:
COMPLETED
Status Verified Date:
2022-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A study of palbociclib in combination with letrozole as treatment of post-menopausal women with hormone receptor-positive her2-negative advanced breast cancer for whom letrozole therapy is deemed appropriate
Detailed Description:
To provide access to palbociclib to post-menopausal patients with hormone receptor-positive HR HER2-negative HER2- ABC who are deemed appropriate for letrozole therapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None